Prelude Capital Management, LLC Puma Biotechnology, Inc. Transaction History
Prelude Capital Management, LLC
- $1.23 Billion
- Q1 2025
A detailed history of Prelude Capital Management, LLC transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 37,700 shares of PBYI stock, worth $122,148. This represents 0.01% of its overall portfolio holdings.
Number of Shares
37,700
Previous 24,800
52.02%
Holding current value
$122,148
Previous $75,000
48.0%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding PBYI
# of Institutions
116Shares Held
31MCall Options Held
32.7KPut Options Held
200-
Acorn Capital Advisors, LLC New York, NY3.94MShares$12.8 Million8.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.67MShares$11.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$11.6 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.01MShares$6.51 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.83MShares$5.93 Million0.01% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $148M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...